MIRV Is Safe and Efficacious in FRα-High, Platinum-Resistant Ovarian Cancer

Article navigation

Research Watch| April 03 2023

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2023

American Association for Cancer Research

Cancer Discov (2023) 13 (4): OF5.

Abstract

Mirvetuximab soravtansine (MIRV) met its primary endpoint with an objective response rate of 32.4%.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.